Intriguingly C100, a breast cancer cell line that expresses both Nrp1 and Nrp2, responds to exogenous Sema3f with inhibition of cell spreading, and this response is insensitive to the addition of anti-Nrp1 functional blocking antibody (Nasarre et al., 2003). Here, SEMA3F is linked to breast cancer.